Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif
A Phase 3 randomized trial reveals that stereotactic radiation significantly outperforms hippocampal-avoidance whole brain radiation in reducing symptom severity and interference with daily living for patients with 5 to 20 brain metastases,
The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increa
The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist
The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit
The Phase 2 LARA trial demonstrates that combining pembrolizumab and lenvatinib yields a 40% objective response rate in recurrent gynaecological clear cell carcinoma, offering a potential new standard for this historically chemo-resistant a
A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile,
A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i
The WOLVERINE individual patient data meta-analysis confirms that metastasis-directed therapy significantly improves progression-free and castration resistance-free survival in oligometastatic prostate cancer, providing high-level evidence
A population-based study in England reveals that correcting socioeconomic and clinical inequalities in the use of minimally invasive surgery for colon cancer significantly reduces hospital stays and 1-year mortality, highlighting a critical
A post-hoc analysis of the nationwide PORSCH trial reveals that algorithm-based care for early recognition and management of postoperative complications significantly improves long-term overall survival in patients undergoing pancreatic res
A single-center study demonstrates that an AI pipeline for CT-based lymph node segmentation and extranodal extension classification significantly improves prognostic accuracy for HPV-positive oropharyngeal cancer compared to traditional rad
A qualitative study published in JAMA Network Open identifies how limited cultural capital, cancer-related stigma, and economic deprivation form a self-reinforcing cycle that excludes low-income patients from hospice care, highlighting the
A prospective multicenter study of 433 patients demonstrates that combining stereotactic radiotherapy with biological cancer therapy is safe, with severe adverse events occurring in less than 10% of cases. Crucially, continuing biological t
A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.
A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to d
A CISNET modeling study demonstrates that mammography screening tailored to 5-year absolute invasive breast cancer risk reduces false-positive recalls by up to 23% while maintaining or improving mortality benefits compared to traditional ag
The European Society of Gynaecological Oncology (ESGO) has released new consensus statements advocating for opportunistic salpingectomy—removing fallopian tubes during unrelated surgeries—to significantly reduce ovarian cancer risk without
A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA <1.0 ng/mL indicating a very low 20-year incidence of 3.3%, supporting extended screening intervals
A large-scale population study confirms that removing fallopian tubes during unrelated pelvic surgeries reduces serous ovarian cancer risk by 78%, providing robust evidence for its use as a primary prevention strategy against high-grade ser
Open language-specific specialty feeds and department pages.